Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Prospective Assessment of Health-Related Quality of Life in Pediatric Patients with Beta-Thalassemia following Hematopoietic Stem Cell Transplantation
Biology of Blood and Marrow Transplantation, Volume 17, No. 6, Year 2011
Notification
URL copied to clipboard!
Description
Although hematopoietic stem cell transplantation (HSCT) has been widely used to treat pediatric patients with beta-thalassemia major, evidence showing whether this treatment improves health-related quality of life (HRQoL) is lacking. We used child-self and parent-proxy reports to prospectively evaluate HRQoL in 28 children with beta-thalassemia from Middle Eastern countries who underwent allogeneic HSCT in Italy. The PedsQL 4.0 Generic Core Scales were administered to patients and their parents 1 month before and 3, 6, and 18 months after transplantation. Two-year overall survival, thalassemia-free survival, mortality, and rejection were 89.3%, 78.6%, 10.9% and 14.3%, respectively. The cumulative incidence of acute and chronic graft-versus-host disease (GVHD) was 36% and 18%, respectively. Physical functioning declined significantly from baseline to 3 months after HSCT (median PedsQL score, 81.3 vs 62.5; P = .02), but then increased significantly up to 18 months after HSCT (median score, 93.7; P = .04). Agreement between child-self and parent-proxy ratings was high. Chronic GVHD was the most significant factor associated with lower HRQoL scores over time (P = .02). The child-self and parent-proxy reports showed improved HRQoL in the children with beta-thalassemia after HSCT. Overall, our study provides preliminary evidence-based data to further support clinical decision making in this area. © 2011 American Society for Blood and Marrow Transplantation.
Authors & Co-Authors
Caocci, G.
Italy, Cagliari
Ats Sardegna, Assl Cagliari Ospedale Binaghi
Efficace, Fabio
Italy, Rome
Italian Group for Adult Hematologic Diseases Gimema Data Center
Ciotti, Francesca
Italy, Milan
Irccs Ospedale San Raffaele
Roncarolo, Maria Grazia
Italy, Milan
Irccs Ospedale San Raffaele
Vacca, Adriana
Italy, Cagliari
Ats Sardegna, Assl Cagliari Ospedale Binaghi
Piras, Eugenia
Italy, Cagliari
Ats Sardegna, Assl Cagliari Ospedale Binaghi
Littera, R.
Italy, Cagliari
Ats Sardegna, Assl Cagliari Ospedale Binaghi
Dawood Markous, Raji Suleiman
Iraq
Hevi Pediatric Hospital
Collins, Gary S.
United Kingdom, Oxford
University of Oxford Medical Sciences Division
Ciceri, Fabio
Italy, Milan
Irccs Ospedale San Raffaele
Mandelli, Franco
Italy, Rome
Italian Group for Adult Hematologic Diseases Gimema Data Center
Marktel, Sarah
Italy, Milan
Irccs Ospedale San Raffaele
La Nasa, G. L.
Italy, Cagliari
Ats Sardegna, Assl Cagliari Ospedale Binaghi
Italy, Cagliari
Università Degli Studi Di Cagliari
Statistics
Citations: 54
Authors: 13
Affiliations: 6
Identifiers
Doi:
10.1016/j.bbmt.2010.09.011
ISSN:
10838791
e-ISSN:
15236536
Research Areas
Disability
Maternal And Child Health
Study Design
Cohort Study